Multicentre randomized phase II study with Gemcitabine (GEM) plus cisplatin (CDDP) in patients with stage IIIB-IV NSCLC

被引：0
|
作者：
Ricci, S
Antonuzzo, A
Galli, L
Algeri, R
Bonifazi, V
Andrei, A
Petruzzelli, S
Dupre, C
Pegna, AL
Conte, PF
机构：
[1] Osped S Chiara, Pisa, Italy
[2] Osped Civile Misericordia, Grosseto, Italy
[3] Osped Cisanello, Pisa, Italy
[4] Osped Careggi, Florence, Italy
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
456
引用
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [41] A phase II trial of high-dose gemcitabine (GEM) plus cisplatin (CDDP) in advanced non small cell lung cancer(NSCLC).: Preliminary results.
    Isla, D
    Mayordom, JI
    Yubero, A
    Cajal, R
    Bueso, P
    Herráez, J
    Martí, JL
    Murillo, L
    Sáenz, A
    Escudero, P
    García-Prats, MD
    Tres, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S67 - S67
  • [42] A phase II prospective study evaluating the role of pemetrexed plus gemcitabine (Pem/Gem) chemotherapy as intial treatment in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) using a genomic predictor of cisplatin-resistance to guide therapy
    Garst, J.
    Datto, M.
    Herndon, J. E., II
    Barry, W. T.
    Shoemaker, D.
    Bjurstrom, A.
    Andrews, C.
    Ginsburg, G.
    Nevins, J. R.
    Potti, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] Histological analysis in pemetrexed treated patients with stage IIIB/IV NSCLC: results from an open label randomized phase II study
    Niho, Seiji
    Kubota, Kaoru
    Enatsu, Sotaro
    Nambu, Yoshihiro
    Nishiwaki, Yutaka
    Saijo, Nagahiro
    Fukuoka, Masahiro
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S533 - S533
  • [44] Phase II study of Gemcitabine (GEM) plus navelbine (NVB) in previously untreated stage III or IV non-small cell lung cancer (NSCLC)
    De Candis, D
    Bidoli, P
    Cresta, S
    Artale, S
    Masi, G
    Bajetta, E
    ANNALS OF ONCOLOGY, 1998, 9 : 95 - 96
  • [45] Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma: A randomized phase II trial
    Hsu, C.
    Cheng, A.
    Shih, J.
    Yu, C.
    Kuo, S.
    Lin, C.
    Huang, T.
    Yang, P.
    Yang, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] A Phase II Study of Erlotinib as Initial Treatment for Patients with Stage IIIB-IV Non-small Cell Lung Cancer
    Akerley, Wallace
    Boucher, Kenneth M.
    Bentz, Joel S.
    Arbogast, Kylee
    Walters, Theodore
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (02) : 214 - 219
  • [47] Five-year outcomes of a phase II study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in stage IIIB-IV(M0) gastric cancer patients
    Yoon, S.
    Ryu, M. H.
    Ryoo, B. Y.
    Kim, K. C.
    Yook, J. H.
    Oh, S. T.
    Kim, B. S.
    Kang, Y. K.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S633 - S633
  • [48] Cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) in advanced (stage IIIB and stage IV) non-small cell lung cancer (NSCLC). A multicenter phase III study
    Kunitoh, H
    Saijo, N
    Nagao, K
    Ohashi, Y
    Niitani, H
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S249 - S250
  • [49] Superiority of three-week vs. four-week schedule of cisplatin (CDDP) and gemcitabine (GEM): Results of a randomized phase II study
    Cavina, R
    Parra, HS
    Antonelli, G
    Latteri, F
    Sala, A
    Dambrosio, M
    Allosio, M
    Morenghi, E
    Bufalino, R
    Carnaghi, C
    Santoro, A
    ANNALS OF ONCOLOGY, 2000, 11 : 2 - 2
  • [50] A cisplatin-gemcitabine-vinorelbine (PVG) first-line treatment in IIIB-IV non small cell lung cancer (NSCLC).
    Portalone, L
    Antilli, A
    Brocchieri, P
    Lombardi, A
    Nunziati, F
    Pezzuto, A
    Signora, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 647S - 647S
12345